At this Cornerstone Research webinar, attorneys, economists and regulators discussed the law and economics underpinning the recent judgments on paroxetine and phenytoin, and the anticipated AG opinion on citalopram.
This expert forum featured panellists from the Competition & Markets Authority (CMA), private practice and academia who considered the impact of recent decisions in reverse payments matters. Several of our speakers had been instructed in significant ongoing cases of this kind, and offered insight based on their practical experience. Topics for discussion included:
- The CMA’s perspectives on how the decisions will affect their approach in reverse payments matters
- The conditions under which settlement agreements are restriction of competition by object and restriction of competition by effect
- Economic analyses that demonstrate whether a settlement agreement does or does not have appreciable potential or real effects on competition.